Alpha-synuclein aggregation induced by brief ischemia negatively impacts neuronal survival in vivo: A study in A30Palpha-synuclein transgenic mouse

Journal of Cerebral Blood Flow and Metabolism

Volumn 31, Issue 3, 2011, Pages 913-923

  Unal Cevik, Isin ^a,d   Gursoy Ozdemir, Yasemin ^a   Yemisci, Muge ^a   Lule, Sevda ^a   Gurer, Gunfer ^a   Can, Alp ^b   Müller, Veronica ^c   Kahle, Philip J ^c,e   Dalkara, Turgay ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

^c UNIVERSITY OF MUNICH   (Germany)

^d UFUK UNIVERSITY   (Turkey)

^e UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

alpha synuclein; focal cerebral ischemia; neurodegeneration; protein aggregation; selective neuronal necrosis; A30P alpha synuclein mutation

Indexed keywords

3 NITROTYROSINE; ALPHA SYNUCLEIN; BETA SYNUCLEIN; OLIGOMER; UBIQUITIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CELL SURVIVAL; CONTROLLED STUDY; IMMUNOREACTIVITY; IN VIVO STUDY; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NERVE CELL NECROSIS; NITRATIVE STRESS; NONHUMAN; OLIGOMERIZATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN LOCALIZATION; REPERFUSION; TRANSGENIC MOUSE; WILD TYPE;

EID: 85027948550     PISSN: 0271678X     EISSN: None     Source Type: Journal    
DOI: 10.1038/jcbfm.2010.170     Document Type: Article

References (50)

1. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431:805-10 (Pubitemid 39434070)
2. Arsava EM, Gurer G, Gursoy-Ozdemir Y, Karatas H, Dalkara T (2009) A new model of transient focal cerebral ischemia for inducing selective neuronal necrosis. Brain Res Bull 78:226-31
3. Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, Trojanowski JQ, Iwatsubo T (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 152:879-84 (Pubitemid 28173348)
4. Burn DJ (2006) Cortical Lewy body disease and Parkinson's disease dementia. Curr Opin Neurol 19:572-9 (Pubitemid 44760441)
5. Conway KA, Harper JD, Lansbury PT (1998) Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 4:1318-20 (Pubitemid 28512115)
6. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury Jr PT (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 97:571-6 (Pubitemid 30070350)
7. DeGracia DJ, Montie HL (2004) Cerebral ischemia and the unfolded protein response. J Neurochem 91:1-8 (Pubitemid 39314931)
8. Freichel C, Neumann M, Ballard T, Muller V, Woolley M, Ozmen L, Borroni E, Kretzschmar HA, Haass C, Spooren W, Kahle PJ (2007) Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice. Neurobiol Aging 28:1421-35 (Pubitemid 47081234)
9. Giasson BI, Uryu K, Trojanowski JQ, Lee VM (1999) Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem 274:7619-22
10. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290:985-9
11. Giasson BI, Murray IV, Trojanowski JQ, Lee VM (2001) A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem 276:2380-6
12. Goedert M (2001) The significance of tau and alpha-synuclein inclusions in neurodegenerative diseases. Curr Opin Genet Dev 11:343-51 (Pubitemid 32480303)
13. Gursoy-Ozdemir Y, Bolay H, Saribas O, Dalkara T (2000) Role of endothelial nitric oxide generation and perox-ynitrite formation in reperfusion injury after focal cerebral ischemia. Stroke 31:1974-80; discussion 81
14. Hu BR, Martone ME, Jones YZ, Liu CL (2000) Protein aggregation after transient cerebral ischemia. J Neurosci 20:3191-9 (Pubitemid 30263136)
15. Hu BR, Janelidze S, Ginsberg MD, Busto R, Perez-Pinzon M, Sick TJ, Siesjo BK, Liu CL (2001) Protein aggregation after focal brain ischemia and reperfusion. J Cereb Blood Flow Metab 21:865-75 (Pubitemid 32613541)
16. Jakes R, Spillantini MG, Goedert M (1994) Identification of two distinct synucleins from human brain. FEBS Lett 345:27-32 (Pubitemid 24154659)
17. Jakes R, Crowther RA, Lee VM, Trojanowski JQ, Iwatsubo T, Goedert M (1999) Epitope mapping of LB509, a monoclonal antibody directed against human alpha-synuclein. Neurosci Lett 269:13-6 (Pubitemid 29305690)
18. Kahle PJ, Neumann M, Ozmen L, Muller V, Jacobsen H, Schindzielorz A, Okochi M, Leimer U, van Der Putten H, Probst A, Kremmer E, Kretzschmar HA, Haass C (2000) Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain. J Neurosci 20:6365-73
19. Kahle PJ, Neumann M, Ozmen L, Muller V, Odoy S, Okamoto N, Jacobsen H, Iwatsubo T, Trojanowski JQ, Takahashi H, Wakabayashi K, Bogdanovic N, Riederer P, Kretzschmar HA, Haass C (2001) Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol 159:2215-25 (Pubitemid 33104275)
20. Kaya D, Gursoy-Ozdemir Y, Yemisci M, Tuncer N, Aktan S, Dalkara T (2005) VEGF protects brain against focal ischemia without increasing blood-brain permeability when administered intracerebroventricularly. J Cereb Blood Flow Metab 25:1111-8 (Pubitemid 41710737)
21. Kilinc M, Gürsoy-Ozdemir Y, Gürer G, Erdener SE, Erdemli E, Can A, Dalkara T (2010) Lysosomal rupture, necroapoptotic interactions and potential crosstalk between cysteine proteases in neurons shortly after focal ischemia. Neurobiol Dis 40:293-302
22. Kopito RR (2000) Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 10:524-30
23. Kramer ML, Schulz-Schaeffer WJ (2007) Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurode-generation in dementia with Lewy bodies. J Neurosci 27:1405-10
24. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O (1998) Ala30Pro mutation in the gene encoding alpha-synu-clein in Parkinson's disease. Nat Genet 18:106-8
25. Lange MS, Johnston MV, Tseng EE, Baumgartner WA, Blue ME (1999) Apoptosis detection in brain using low-magnification dark-field microscopy. Exp Neurol 158:254-60 (Pubitemid 29344339)
26. Lee M, Hyun D, Halliwell B, Jenner P (2001) Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J Neurochem 76: 998-1009 (Pubitemid 32167373)
27. Lee VM, Trojanowski JQ (2006) Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron 52:33-8 (Pubitemid 44479831)
28. Manning-Bog AB, McCormack AL, Purisai MG, Bolin LM, Di Monte DA (2003) Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J Neurosci 23:3095-9 (Pubitemid 36531948)
29. Maroteaux L, Scheller RH (1991) The rat brain synucleins; family of proteins transiently associated with neuronal membrane. Brain Res Mol Brain Res 11:335-43
30. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegen-erative disorders. Science 287:1265-9 (Pubitemid 30112148)
31. Matsuzaki M, Hasegawa T, Takeda A, Kikuchi A, Furukawa K, Kato Y, Itoyama Y (2004) Histochemical features of stress-induced aggregates in alpha-synuclein overex-pressing cells. Brain Res 1004:83-90 (Pubitemid 38368064)
32. Miake H, Mizusawa H, Iwatsubo T, Hasegawa M (2002) Biochemical characterization of the core structure of alpha-synuclein filaments. J Biol Chem 277:19213-9 (Pubitemid 34952489)
33. Narhi L, Wood SJ, Steavenson S, Jiang Y, Wu GM, Anafi D, Kaufman SA, Martin F, Sitney K, Denis P, Louis JC, Wypych J, Biere AL, Citron M (1999) Both familial Parkinson's disease mutations accelerate alpha-synu-clein aggregation. J Biol Chem 274:9843-6
34. Neumann M, Kahle PJ, Giasson BI, Ozmen L, Borroni E, Spooren W, Muller V, Odoy S, Fujiwara H, Hasegawa M, Iwatsubo T, Trojanowski JQ, Kretzschmar HA, Haass C (2002) Misfolded proteinase K-resistant hyper-phosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest 110:1429-39 (Pubitemid 35396914)
35. Nonaka T, Iwatsubo T, Hasegawa M (2005) Ubiquitination of alpha-synuclein. Biochemistry 44:361-8
36. Parkkinen L, Kauppinen T, Pirttila T, Autere JM, Alafuzoff I (2005) Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 57:82-91 (Pubitemid 40053318)
37. Paschen W, Mengesdorf T (2005) Cellular abnormalities linked to endoplasmic reticulum dysfunction in cere-brovascular disease-therapeutic potential. Pharmacol Ther 108:362-75 (Pubitemid 41693766)
38. Ross CA, Poirier MA (2005) Opinion: what is the role of protein aggregation in neurodegeneration? Nat Rev Mol Cell Biol 6:891-8 (Pubitemid 41568738)
39. Schulz-Schaeffer WJ (2002) [BSE and variant CJD: about the difficulties to establish a new pathogenetic principle]. Dtsch Med Wochenschr 127:344-6 (Pubitemid 34158083)
40. Soto C (2003) Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci 4:49-60 (Pubitemid 37271088)
41. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388:839-40
42. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M (1998) Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 95:6469-73 (Pubitemid 28249037)
43. Tu PH, Galvin JE, Baba M, Giasson B, Tomita T, Leight S, Nakajo S, Iwatsubo T, Trojanowski JQ, Lee VM (1998) Glial cytoplasmic inclusions in white matter oligoden-drocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol 44:415-22 (Pubitemid 28421453)
44. Ueda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M, Otero DA, Kondo J, Ihara Y, Saitoh T (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA 90:11282-6 (Pubitemid 23354413)
45. Unal-Cevik I, Kilinç M, Can A, Gürsoy-Ozdemir Y, Dalkara T (2004) Apoptotic and necrotic death mechanisms are concomitantly activated in the same cell after cerebral ischemia. Stroke 35:2189-94 (Pubitemid 39129584)
46. Uryu K, Chen XH, Martinez D, Browne KD, Johnson VE, Graham DI, Lee VM, Trojanowski JQ, Smith DH (2007) Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans. Exp Neurol 208:185-92 (Pubitemid 350101496)
47. Van Der Putten H, Wiederhold KH, Probst A, Barbieri S, Mistl C, Danner S, Kauffmann S, Hofele K, Spooren WP, Ruegg MA, Lin S, Caroni P, Sommer B, Tolnay M, Bilbe G (2000) Neuropathology in mice expressing human alpha-synuclein. J Neurosci 20:6021-9 (Pubitemid 30658395)
48. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM (2003) Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 348:1215-22 (Pubitemid 36359297)
49. Vila M, Vukosavic S, Jackson-Lewis V, Neystat M, Jakowec M, Przedborski S (2000) Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the Parkinsonian toxin MPTP. J Neurochem 74:721-9 (Pubitemid 30053745)
50. Wood SJ, Wypych J, Steavenson S, Louis JC, Citron M, Biere AL (1999) Alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogen-esis of Parkinson's disease. J Biol Chem 274:19509-12